Microdosing semaglutide Some prescribers use doses below the standard starting point (less than 0.25 mg) for patients who are particularly sensitive to GLP-1 medications or who have a history of severe nausea with other medications
In mice bearing colon carcinoma C26, BPC 157 therapy counteracts severe muscle cachexia and weight loss, improving anabolic pathways while counteracting catabolic pathways and cachexia mediators and, most importantly, prolonging survival time [22]
BPC-157 is not currently approved by the Therapeutic Goods Administration (TGA) for any therapeutic use in Australia
Main Therapeutic Indications: Neuritis and Neuralgia: Effectively relieves inflammation and stabbing pain in the nerves, being a key ally in the treatment of conditions such as: Cervical syndrome and shoulder-arm syndrome
Medications are dispensed through our licensed partner pharmacies following a successful provider evaluation
In animal models, it has shown potential in accelerating the healing of wounds, promoting the outgrowth of tendon fibroblasts, and cell survival under stress [3]